Amphastar Pharmaceuticals Files 2024 10-K

Ticker: AMPH · Form: 10-K · Filed: Mar 3, 2025 · CIK: 1297184

Amphastar Pharmaceuticals, Inc. 10-K Filing Summary
FieldDetail
CompanyAmphastar Pharmaceuticals, Inc. (AMPH)
Form Type10-K
Filed DateMar 3, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals, debt

TL;DR

AMPH 2024 10-K filed. Financials and debt details out.

AI Summary

Amphastar Pharmaceuticals, Inc. filed its 2024 10-K on March 3, 2025, reporting its fiscal year ending December 31, 2024. The filing details the company's financial performance and business operations. Key financial data points and disclosures regarding long-term debt and capital lease obligations are included, referencing FASB standards.

Why It Matters

This filing provides investors and analysts with a comprehensive overview of Amphastar's financial health and strategic positioning for the fiscal year 2024, influencing investment decisions.

Risk Assessment

Risk Level: medium — The filing is a standard annual report and does not inherently indicate new or elevated risks.

Key Numbers

  • 2024 — Fiscal Year End (The period covered by the 10-K filing.)
  • 2023 — Prior Fiscal Year End (For comparison with the current fiscal year's performance.)
  • 2025-03-03 — Filing Date (The date Amphastar Pharmaceuticals, Inc. submitted this 10-K.)

Key Players & Entities

  • Amphastar Pharmaceuticals, Inc. (company) — Filer of the 10-K
  • 2024-12-31 (date) — Fiscal year end
  • 2025-03-03 (date) — Filing date
  • 11570 SIXTH STREET (address) — Company business and mail address
  • RANCHO CUCAMONGA, CA 91730 (address) — Company business and mail city, state, zip
  • 909-980-9484 (phone_number) — Company business phone
  • 001-36509 (filing_number) — SEC file number
  • 25698138 (film_number) — SEC film number
  • Wells Fargo Bank (company) — Mentioned in relation to debt
  • Two Thousand Twenty Nine (date) — Maturity year for convertible notes

FAQ

What were Amphastar Pharmaceuticals' total revenues for the fiscal year ending December 31, 2024?

The filing does not explicitly state the total revenues for the fiscal year ending December 31, 2024, within the provided header information. Detailed financial statements would be required to ascertain this figure.

What is the company's primary business address?

The company's business address is 11570 SIXTH STREET, RANCHO CUCAMONGA, CA 91730.

When are the Amphastar Pharmaceuticals' Two Percent Convertible Senior Notes due?

The Two Percent Convertible Senior Notes are due in Two Thousand Twenty Nine (2029).

What is the SEC file number for Amphastar Pharmaceuticals?

The SEC file number for Amphastar Pharmaceuticals is 001-36509.

Does the filing mention any specific debt instruments beyond convertible notes?

Yes, the filing references 'us-gaap:SecuredDebtMember' and 'amph:WellsFargoBankMember' in the context of debt as of December 31, 2024.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 3, 2025 regarding Amphastar Pharmaceuticals, Inc. (AMPH).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.